Healthequity (NASDAQ:HQY) issued an update on its FY 2020
After-Hours earnings guidance on Tuesday morning. The company provided EPS guidance of 1.46-1.52 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.28. The company issued revenue guidance of $520-526 million, compared to the consensus revenue estimate of $517.31 million.

Shares of HQY traded down $0.30 on Tuesday, hitting $61.24. The company’s stock had a trading volume of 803,199 shares, compared to its average volume of 901,225. The company has a market capitalization of $4.44 billion, a PE ratio of 64.46, a PEG ratio of 2.87 and a beta of 1.47. The company has a debt-to-equity ratio of 0.04, a current ratio of 22.98 and a quick ratio of 22.98. Healthequity has a fifty-two week low of $50.29 and a fifty-two week high of $91.19. The company has a 50 day moving average price of $59.64 and a 200 day moving average price of $64.25.

Healthequity (NASDAQ:HQY) last released its quarterly earnings results on Tuesday, September 3rd. The company reported $0.36 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.10. Healthequity had a return on equity of 11.77% and a net margin of 28.13%. The firm had revenue of $86.60 million during the quarter, compared to analysts’ expectations of $85.33 million. During the same period last year, the firm posted $0.36 EPS. The business’s revenue was up 21.8% on a year-over-year basis. On average, equities analysts forecast that Healthequity will post 0.87 EPS for the current year.

A number of research firms have commented on HQY. KeyCorp set a $70.00 price objective on Healthequity and gave the stock a buy rating in a research note on Monday, September 30th. BidaskClub upgraded Healthequity from a sell rating to a hold rating in a research note on Wednesday, November 6th. SunTrust Banks reduced their price target on shares of Healthequity to $80.00 and set a buy rating on the stock in a research report on Monday, September 9th. Deutsche Bank started coverage on shares of Healthequity in a research report on Thursday, September 12th. They set a buy rating and a $74.00 price target on the stock. Finally, ValuEngine lowered shares of Healthequity from a buy rating to a hold rating in a report on Tuesday, August 6th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Healthequity presently has a consensus rating of Buy and an average price target of $77.00.

In other news, CFO Darcy G. Mott sold 4,000 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $60.39, for a total transaction of $241,560.00. Following the transaction, the chief financial officer now owns 38,000 shares of the company’s stock, valued at $2,294,820. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 12,000 shares of company stock valued at $715,600. 3.70% of the stock is currently owned by corporate insiders.

Healthequity Company Profile

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Further Reading: Sell-Side Analysts

Earnings History and Estimates for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.